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Abstract
The progressive ataxias are a group of rare and complicated neurological disorders, knowledge of which is often
poor among healthcare professionals (HCPs). The patient support group Ataxia UK, recognising the lack of
awareness of this group of conditions, has developed medical guidelines for the diagnosis and management of
ataxia. Although ataxia can be a symptom of many common conditions, the focus here is on the progressive
ataxias, and include hereditary ataxia (e.g. spinocerebellar ataxia (SCA), Friedreich’s ataxia (FRDA)), idiopathic
sporadic cerebellar ataxia, and specific neurodegenerative disorders in which ataxia is the dominant symptom (e.g.
cerebellar variant of multiple systems atrophy (MSA-C)). Over 100 different disorders can lead to ataxia, so diagnosis
can be challenging. Although there are no disease-modifying treatments for most of these entities, many aspects of
the conditions are treatable, and their identification by HCPs is vital. The early diagnosis and management of the
(currently) few reversible causes are also of paramount importance. More than 30 UK health professionals with
experience in the field contributed to the guidelines, their input reflecting their respective clinical expertise in
various aspects of ataxia diagnosis and management. They reviewed the published literature in their fields, and
provided summaries on “best” practice, including the grading of evidence available for interventions, using the
Guideline International Network (GIN) criteria, in the relevant sections.
A Guideline Development Group, consisting of ataxia specialist neurologists and representatives of Ataxia UK
(including patients and carers), reviewed all sections, produced recommendations with levels of evidence, and
discussed modifications (where necessary) with contributors until consensus was reached. Where no specific
published data existed, recommendations were based on data related to similar conditions (e.g. multiple sclerosis)
and/or expert opinion. The guidelines aim to assist HCPs when caring for patients with progressive ataxia, indicate
evidence-based (where it exists) and best practice, and act overall as a useful resource for clinicians involved in
managing ataxic patients. They do, however, also highlight the urgent need to develop effective disease-modifying
treatments, and, given the large number of recommendations based on “good practice points”, emphasise the
need for further research to provide evidence for effective symptomatic therapies.
These guidelines are aimed predominantly at HCPs in secondary care (such as general neurologists, clinical
geneticists, physiotherapists, speech and language therapists, occupational therapists, etc.) who provide care for
individuals with progressive ataxia and their families, and not ataxia specialists. It is a useful, practical tool to forward
to HCPs at the time referrals are made for on-going care, for example in the community.
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Introduction
The progressive ataxias are a heterogenous group of (in-
dividually) rare neurological conditions. Epidemiological
evidence is lacking, but recent estimates suggest that
there are at least 10,000 adults and 500 children with
progressive ataxia in the UK [1, 2]. Whereas incidence
rates for the progressive ataxias collectively are not
known, some specific conditions have been well charac-
terised. For example, Friedreich’s ataxia (FRDA), the
most common inherited ataxia, has an estimated inci-
dence rate of 1:29,000 amongst Caucasians [3].
The word ataxia means ‘lack of coordination’, and
these conditions typically present with unsteadiness and
imbalance, clumsiness, and slurred speech. Gait and bal-
ance problems often progress to the point at which pa-
tients become wheelchair-bound, and, in general, the
level of disability progresses at the cost of functional in-
dependence. Communication becomes progressively im-
paired as a result of speech disturbances. Various other
symptoms are associated with specific ataxia conditions,
including spasticity, tremor, sensory disturbance, auditory
and visual impairment, bladder and bowel dysfunction,
cardiac complications, musculoskeletal complications, and
cognitive impairment.
These rare and complex conditions present a signifi-
cant diagnostic challenge, and both patients and clini-
cians alike have reported inefficient and arduous
journeys which often fail to establish a definitive cause
[4]. Beyond diagnosis, understanding of management
options amongst HCPs is lacking, and as such patients
face enormous challenges in both understanding their
illness and obtaining treatment. Despite the absence of
disease-modifying treatments for most ataxias, many as-
pects of these disorders are treatable, and it is essential
that the responsible HCPs know how best to manage
these symptoms optimally. The aim of these guidelines
is therefore to increase awareness of these conditions
among non-specialists HCPs (mostly in secondary care,
such as general neurologists, clinical geneticists, physio-
therapists, speech and language therapists, occupational
therapists, etc.), and to improve their diagnosis and
management. Recently the guidelines were affirmed and
considered ready for dissemination by the European Ref-
erence Network for Rare Neurological Diseases, highlight-
ing their recognition internationally.
These guidelines focus on the progressive ataxias, and
exclude disorders where ataxia is an epiphenomenon of
another neurological condition. Specifically, the recom-
mendations cover the inherited ataxias (e.g. FRDA,
SCAs), idiopathic sporadic cerebellar ataxia and specific
neurological conditions in which ataxia is the dominant
symptom (e.g. MSA-C). Of note, these guidelines do not
cover ataxia that results from vascular, inflammatory or
neoplastic pathology. In addition, information about the
extra-neurological features of Ataxia Telangiectasia are
not included in these guidelines, but these are covered
elsewhere [5].
Methods
The guidelines have been developed under the aegis of
the patient support organisation, Ataxia UK, through ex-
tensive consultation with numerous UK neurologists,
and other specialist physicians, surgeons, and therapists
with experience in the diagnosis and management of
ataxia. Contributors for each section were selected on
account of their clinical expertise in aspects of ataxia
diagnosis and management. More than 30 UK health
professionals (please see Additional file 1: Table S1) con-
tributed. They reviewed the available medical literature
for their section using standard databases (e.g. PubMed,
MEDLINE, Cochrane Database of Systematic Reviews,
EMBASE and Scopus) and provided scientific evidence
for the efficacy of different interventions. They graded
the level of evidence following the Guideline Inter-
national Network (GIN) protocol [6]. This included con-
tributors critically reviewing the scientific evidence for
the efficacy of interventions. For each paper, a judge-
ment was made on the level of evidence (I to IV), any
uncertainty was documented, and pertinent conclusions
were drawn.
Earlier versions of the Ataxia UK guidelines (in 2007
and 2009) did not attempt to grade the quality of evi-
dence supporting recommendations. In this iteration,
data on the level of available evidence were used to allo-
cate a grade to each recommendation, in accordance
with criteria used internationally [7, 8]. Table 1 details
the level of evidence and scheme for grading recommen-
dations in these guidelines.
A Guideline Development Group consisting of neurol-
ogists with expertise in ataxia and representatives of
Ataxia UK reviewed all the sections and discussed any
changes with contributors consensually.
Results
The guidelines comprise 128 recommendations, grouped
in four sections- on diagnosis and medical interventions,
with two additional sections (available here in the Add-
itional file 1) relating to in depth information about holis-
tic/multi-disciplinary therapy and palliative care. Grading
of the 128 recommendations were as follows: 6 graded B,
7 graded C, 10 graded D, and 105 graded as GPP. The full
guidelines are available on the Ataxia UK website (https://
www.ataxia.org.uk/Pages/Category/medical-guidelines).
Diagnosis
The ataxias can present in a variety of ways, so an accur-
ate and comprehensive history, together with clinical
examination and relevant investigations are essential for
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efficient diagnosis and management. Important consider-
ations in the history include the speed of symptom evo-
lution, age at onset and family history. Patients with
ataxia will typically report incoordination and unsteadi-
ness, clumsiness, and slurred speech, and clinical signs
include gait ataxia, nystagmus, hyper/hypometropic sac-
cades and jerky pursuit when eye movements are
assessed, slurred speech, intention tremor, dysmetria (or
‘past-pointing’), and dysdiadochokinesis. Diagnostic in-
vestigations are numerous and range from simple blood
tests to next generation sequencing (NGS) panels, nerve
conduction studies, lumbar puncture, and neuroimaging.
Detailed information on tests that can be completed in
primary and secondary care are shown in Table 2.
Rating scales to document the degree of impairment
associated with ataxia are available, both generic (e.g.
Scale for the Assessment and Rating of Ataxa (SARA),
International Cooperative Ataxia Rating Scale (ICARS))
and specific for individuals forms of ataxia (e.g. Frie-
dreich’s Ataxia Rating Scale (FARS)). Monitoring of
ataxic patients’ impairments with one or more of these
scales facilitates the objective recording of progression
with time and enables the unbiased appraisal of inter-
ventions that are carried out. These measurements are
frequently used in clinical trials of disease-modifying
therapies, and in time are likely to become mandatory
when such therapies are utilised in daily clinical practice
(to monitor objectively the impact of such therapies on
individual patients).
Table 3 summarises the main recommendations in this
section.
Medical interventions
As indicated earlier, many of the interventions to amelior-
ate the accompanying (usually neurological) complications
Table 1 Evidence grading scheme for these guidelines
Level of evidence [7]
I Evidence obtained from a systematic review of all relevant
randomised controlled trials.
II Evidence obtained from at least one randomised controlled
trial.
III-a Evidence obtained from one or more controlled trials, pseudo-
randomised by alternate allocation, birth date or other planned
method.
III-b Evidence obtained from prospective or retrospective cohort
studies with concurrent controls, case-control studies, or inter-
rupted time-series with a control group.
III-c Evidence obtained from cohort studies with historical controls,
two or more single-arm studies, or interrupted time-series with-
out a parallel control group.
IV Evidence comprises opinions based on clinical experience,
descriptive studies or reports by clinical bodies or committees.
Grading of recommendations [8]
A Body of evidence can be trusted to guide practice; includes one
or more level I studies, or several at level II directly applicable to
the target population, and demonstrating overall consistency of
results.
B Body of evidence can be trusted to guide practice in most
situations; includes one or two studies rated as level II or several
level III studies, directly applicable to the target population, and
demonstrating overall consistency of results.
C Body of evidence provides some support for
recommendation(s) but care should be taken in its application;
includes studies rated as III-c, or level I or II with a moderate risk
of bias, some inconsistency and applicable to target population
with caveats. Population studied is not the target population,
however, it would make sense clinically to apply this evidence
to target population.
D Body of evidence is weak and recommendation must be
applied with caution; includes level IV, or level I to IV studies
with high risk of bias, inconsistent evidence and that are not
applicable to target population.
GPP
Good practice point: Recommended best practice based on
clinical experience and expert opinion.



















Genetic tests for FRDA, SCA 1, 2, 3, 6,
7 (12, 17) and FXTAS
Lactate
Lipid-adjusted vitamin E and lipoproteins
Lumbar puncture (cells, protein, glucose, cytology,
oligoclonal bands, lactate, ferritin)





CT (chest, abdomen, pelvis)









Very long chain fatty acids
Muscle biopsy
Ophthalmology/OCT
Peripheral nerve conduction studies
Phytanic acid
Remaining genetic tests (NGS)
Total body PET scan
White cell enzymes
U&Es Urea and Electrolytes, FBC Full Blood Count, ESR Erythrocyte Sedimentation Rate, CRP C-Reactive Protein, γ-GT gamma-Glutamyltransferase, TFT Thyroid
Function Test, CXR Chest X-ray, αFP alpha-Fetoprotein, GAD Glutamic Acid Decarboxylase, VGCC Voltage-gated Calcium Channel, CT Computerised Tomography,
FRDA Friedreich’s Ataxia, SCA Spinocerebellar Ataxia, FXTAS Fragile X Tremor-Ataxia Syndrome, CSF Cerebrospinal Fluid, OCT Optical coherence tomography, NGS
Next Generation Sequencing, PET Positron Emission Tomography
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in patients with ataxia are extrapolated from other condi-
tions. The principles governing the management of spasti-
city and bladder symptoms could, for example, be equally
well apply to patients with multiple sclerosis. In Table 4,
key recommendations pertaining to the management of
symptoms manifesting in ataxic patients are presented.
The recommendations also cover some specific hereditary
causes of ataxia, such as Episodic Ataxia type 2- where
symptomatic therapies have the capacity to reduce the se-
verity of, if not abort, bouts of ataxia.
To view the full content of the Medical intervention
section, please see (https://www.ataxia.org.uk/Pages/
News/Category/medical-interventions).
Treatable ataxias
A small number of conditions presenting with ataxia are
amenable to treatment, so diagnosing these is of great
importance. Table 5 lists the treatable ataxias in adults
and children, and recommendations for their diagnosis
and treatment. Table 6 lists recommendations for the
treatment of ataxias diagnosed specifically in childhood.
Allied health professional interventions
Interventions by allied health professionals play a crucial
role in the management of people with progressive
ataxias. Additional file 1: Table S2 in the supplementary
data highlights the key recommendations in the fields of
physiotherapy, speech and language therapy and occupa-
tional therapy, and more detailed recommendations are
available at https://www.ataxia.org.uk/Pages/News/Cat-
egory/allied-health-professional-interventions. This sec-
tion of the guidelines is especially valuable when
referrals are made outside of specialist ataxia centres
and their multidisciplinary teams, when it is recom-
mended that on-going, “maintenance” therapy is carried
out by community teams.
Palliative care
Palliative care is an important element of the holistic
care of individuals living with incurable conditions and
their families, and aims to prevent and relieve suffering
by means of the early identification, comprehensive as-
sessment and treatment of pain and other complications
(encompassing the physical, psychosocial and spiritual
domains) [11]. Where appropriate, palliative care also in-
cludes end-of-life planning and care. In the absence of
available literature on palliative and end-of-life care in the
ataxias specifically, these recommendations are derived in
part from evidence of these interventions in other progres-
sive neurodegenerative conditions [12]. The main recom-
mendations are summarised in Additional file 1: Table S3
in the supplementary data, and available in more detail at
https://www.ataxia.org.uk/palliative-care.
Conclusions and further research
When summarising the grades of evidence available for
the recommendations highlighted in this paper, the large
majority are of “Good Practice Point” standard and as
such are based on clinical experience and anecdotal evi-
dence. It is disappointing that more research has not
been undertaken to support the evidence base of these
interventions in clinical practice. An example is the
many promising pilot studies in Physiotherapy, which
have not been taken forward to larger randomised con-
trolled trials (RCTs). Similarly, there are numerous
pharmacological therapies that are being explored in
Table 3 Diagnosis
Recommendations Grade
The clinical context (speed of evolution, episodic/fluctuating versus progressive etc.) should determine the investigation of individual cases. GPP
Ataxia in adults can arise due to serious neurological disease and urgent referral for secondary care (to a neurologist) should be made
without delay following primary care investigation.
GPP
Children presenting with ataxic symptoms should be referred urgently for paediatric assessment (usually by local specialists, who may liaise
with paediatric neurologists, clinical geneticists, etc).
GPP
Rapid progression (over weeks or months) can denote a paraneoplastic cause, prion disease or multiple system atrophy, thus urgent
investigations are required.
GPP
When a diagnosis of progressive ataxia is made referral to a Specialist Ataxia Centre is encouraged. GPP
Neurologists should liaise with their clinical genetics counterparts given the potential implication for family members of patients who
undergo genetic testing.
GPP
Informed consent should be sought from all those undergoing genetic testing. GPP
It is essential to offer genetic counselling to patients and discuss the implications of a genetic test prior to testing. GPP
Genetic counselling should include the implications of having a genetic test for the individual and their family and any reproductive choices
they may make.
GPP
Asymptomatic ‘at risk’ subjects should be offered genetic counselling. GPP
Genetic testing of asymptomatic ‘at-risk’ minors is not generally recommended, but should be considered on a case-by-case basis. GPP
Any genetic test results from research studies need to be validated by an accredited laboratory before a formal result is given to the patient. GPP
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Table 4 Symptomatic treatments
4.1 Spasticity
Recommendation Grade
Careful assessment by a neurologist, with advice from a
physiotherapist, is required to decide on the type of
treatment of spasticity.
GPP
Consider physiotherapy first to treat spasticity, and if that
does not provide complete benefit use pharmacological
treatment. Surgery should be considered in cases where
physiotherapy and pharmacological treatments have not
worked.
GPP
For pharmacological treatment of generalised spasticity
consider using the following oral medications (usually in this
order due to the profile of side effects and better
tolerability): baclofen, tizanidine, gabapentin, clonazepam,
dantrolene sodium or diazepam.
GPP
To treat focal spasticity refer to a specialised clinic for





Patients with ataxia who have tremors should be offered
pharmacological treatment using Propranolol, Primidone,
Propranolol and Primidone in combination, Topiramate,
Clonazepam and Gabapentin (in this order).
GPP
In patients where tremor is extremely debilitating and not
responsive to medication a referral to a centre specialising in




Focal dystonia should be treated with botulinum toxin
injections.
GPP
Generalised dystonia should be treated with oral
medications, followed by surgery if this is not effective.
GPP
Patients with dystonic tremor should be offered
physiotherapy and oral medications followed by surgery if




Regular surveillance of the development of scoliosis in FRDA
patients (especially children) is recommended as it is
important for it to be treated.
GPP
If scoliosis is detected, referral to a physiotherapist and spinal
surgeon is recommended.
GPP
For mild scoliosis the patient should be kept under close
observation and the spinal surgeon should consider
treatment with bracing.
B [19–21]
For severe scoliosis consider surgery to straighten the spine. B [22, 23]
Regular follow-up by a spinal surgeon is recommended after




Treat pain with physiotherapy and/or pharmacological
treatments.
GPP
Consider use of the following drugs to treat neuropathic
pain: Amitriptyline, Nortriptyline, Carbamazipine, Pregabalin,
Gabapentin and Duloxetine.
GPP
Table 4 Symptomatic treatments (Continued)
Consider referral to a pain management clinic if pain is
severe or limiting daily activities.
GPP
4.6 Cardiac involvement in FRDA
Recommendation Grade
When FRDA is diagnosed a referral to a cardiologist is
recommended for the early diagnosis of cardiac problems
and the management of cardiac complications, where
required.
GPP
Regular screening by a cardiologist is recommended in
FRDA patients; once every two years before any cardiac
disease is documented, and at least annually after
manifesting features of asymptomatic cardiac disease.
GPP
Transthoracic Echocardiography and ECG should be used for
the diagnosis and monitoring of the myocardial changes.
GPP
Holter monitoring should be undertaken to detect silent
cardiac arrhythmias or the association of symptoms (such as
palpitations, shortness of breath) with the underlying
rhythm.
GPP
A cardiologist should consider pharmacological treatment
(including the use of anticoagulants), and in some cases the
implantation of pacing devices, in collaboration with the
neurologist.
GPP
4.7 Bladder problems - lower urinary tract dysfunction
Recommendation Grade
In primary care, test for urinary tract infection and measure
post-void residual (to exclude common causes of urgency
and frequency). If these are normal, check for other common
causes such as prostate enlargement.
GPP
Practical advice should be given about cutting down
caffeine, fizzy drinks and alcohol, as well as information
about timed voiding and bladder retraining whenever
appropriate. The fluid intake should be individualized; a fluid
intake of between 1 to 2 L a day is recommended (taking
into consideration possible concurrent cardiac issues).
GPP
Advice on pelvic floor exercises should be given as it may
be helpful especially when symptoms are mild.
GPP
Most individuals with overactive bladder symptoms will
require antimuscarinic medications (such as tolterodine,
oxybutynin, propiverine and solifenacin).
GPP
In patients with cardiac complications and/or cognitive
problems caution is advised when using antimuscarinic
medications.
GPP
In patients with cognitive problems, more selectively-acting
antimuscarinic medications, such as trospium chloride or dar-
ifenacin should be considered.
GPP
In some instances, referral to an urologist is recommended





Suggest changes in lifestyle (eg: diet, fluid and mobility
assistance) for patients with constipation, followed by the
use of laxatives or suppositories.
GPP
Consider referral for specialist assessment if patients have




Silva et al. Orphanet Journal of Rare Diseases           (2019) 14:51 Page 5 of 10
pilot trials that need further investigation in larger, ap-
propriately controlled studies.
In an era of limited health funding, the absence of evi-
dence (through lack of trials rather than trials failing to
prove efficacy) may be used to argue that these interven-
tions should not be made available to ataxic patients,
through publicly funded healthcare providers, such as
the National Health Service in the UK. The need for fur-
ther research is thus of paramount importance.
It is also of interest to note the limitations of the grading
system adopted in the guidelines. There are some recom-
mendations that do not lend themselves to this method-
ology. As such, these have been graded as Good Practice
Pointers (GPP), as the absence of robust evidence from
RCTs did not enable their categorisation at a higher grade.
An example of this is the recommendation that genetic
Table 4 Symptomatic treatments (Continued)
Consider discussing sexual function with male patients due
to the potential for erectile dysfunction.
GPP
Treat erectile dysfunction where appropriate with
phosphodiesterase-5 inhibitors. Treatment decisions should
balance the needs of the person and the potential side ef-
fect of medications e.g., hypotension.
GPP
If patients have cardiac pathologies caution should be
exercised when considering medication, and consultation
with a cardiologist is recommended.
GPP
4.10 Swallowing and dysphagia
Recommendation Grade
If patients show symptoms of dysphagia a referral to a
speech and language therapist should be made (see
Additional file 1: Table S2).
GPP
If there is unintentional weight loss due to dysphagia
consider the use of nutritional supplements and refer to a
dietician.
GPP
If calorie intake cannot be maintained despite supplements,
discuss the possibility of a percutaneous gastronomy (PEG)
to provide secure feeding.
GPP
4.11 Sialorrhoea (excessive salivation)
Recommendation Grade
Sialorrhoea is normally associated with dysphagia, thus a
referral to a speech and language therapist is recommended
for assessment of swallow.
GPP
Treat sialorrhoea and thick secretions according to Bavikatte
et al. 2012 [9] (and the full guidelines).
GPP
4.12 Audiology and hearing
Recommendation Grade
If a patient is experiencing hearing problems refer to
Audiology services for a battery of hearing tests.
GPP
A hearing aid trial should be considered although it is often
not suitable for this patient population.
GPP
A trial with an FM hearing device is recommended in cases
of ataxia with Auditory Neuropathy Spectrum Disorder
(ANSD).
C [24, 25]
Refer to hearing therapist or speech and language therapist
for guidance on communication tactics.
GPP
For those who do not achieve any benefit from hearing aids,
consider a referral to a cochlear implant centre.
D [26]





A referral to a neuro-ophthalmologist is recommended if
ataxia patients have any eye symptoms.
GPP
If disabling nystagmus or oscillopsia is present treatment is
recommended, often with either gabapentin or baclofen.
B [27–29]
Refer to an optometrist or neuro-ophthalmologist for restor-
ation of single vision with prisms in cases of diplopia.
GPP
Patients with visual impairment should be offered low vision





Table 4 Symptomatic treatments (Continued)
When cognitive impairment is suspected (even if mild)
referral to a Neuropsychology department is recommended.
GPP
Cognitive rehabilitation is recommended for those patients
with cognitive impairment.
C [30]
Characterising the course of the cognitive impairment is
advisable in order to inform the likely prognosis.
GPP
GPP
4.15 Depression and other psychiatric symptoms
Recommendation Grade
In many cases depression can be treated in primary care
using medications, counselling or cognitive behavioural
therapy.
GPP
In more severe or complex cases of depression and other
psychiatric symptoms a referral to a psychiatrist/
neuropsychiatrist in secondary care is recommended.
GPP
For adults consult NICE Guidelines for the treatment of
depression in patients with a chronic physical disorder [10].
GPP
4.16 Inherited episodic ataxias
Recommendation Grade
Advise episodic ataxia patients on identification and
avoidance of common triggers that may cause attacks such
as stress, caffeine and alcohol consumption, and excessive
physical exertion.
GPP
Acetozolamide is recommended as the first line drug in
episodic ataxia types 1 and 2, although not all patients
respond.
GPP
Patients taking acetazolamide should be advised to keep
hydrated to prevent the development of renal calculi and
should undergo annual ultrasound screening of the urinary
tract.
D
Patients with a known hypersensitivity to sulponamides
should be counselled at the start of treatment and need to
be kept under surveillance.
GPP
Consider use of 4-aminopyridine on a named patient basis
as second line drug in episodic ataxia type 2 if acetazol-
amide is not beneficial.
C [31]
In episodic ataxia type 1 consider use of carbamazepine,
phenytoin or lamotrigine as second line treatment.
GPP
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tests are undertaken in accredited laboratories. Although
the intention of this recommendation is for it to be
strongly endorsed (as is self-evident), it may appear weak
as it is graded “GPP”. In instances such as this, the recom-
mendations given do not lend themselves naturally to this
method of grading. Nevertheless, this was only true for a
minority of recommendations made and generally limited
to the section related to diagnosis and to some recom-
mendations on referrals to specialists.
Despite advances in diagnostic testing, many patients
with ataxia are still not given a specific diagnosis of the
underlying cause of their ataxias. The availability of gene
panels, and increasingly exome and whole genome se-
quencing, may offer greater opportunities for the accur-
ate (genetic) characterisation of ataxic subjects and
families. Whilst novel genes responsible for causing
ataxia might emerge, Next Generation Sequencing also
poses challenges, in deciphering the true role of genetic/
genomic variants, and these technological advances need to
be coupled with expert bioinformatics. The determination
of the pathogenicity of “variants of unknown significance”
(VUS) can be time-consuming and expensive. This has
engendered an interest in “deep phenotyping”- where
novel biomarkers and functional assays are utilised to
assist the interpretation of genetic tests. The use of Op-
tical Coherence Tomography (OCT) in supporting the
diagnosis of Autosomal Recessive Spastic Ataxia of
Charlevoix-Saguenay is a recent illustrative example [51].
This type of integrative studies is likely to prove critical in
deciphering the output from NGS (including VUS) over
the next decade.
The production of this third edition of the guidelines
has identified persisting gaps in the management of pa-
tients with ataxia. There is an urgent and pressing need
to develop agents that have a disease-modifying effect in
the ataxias, a need which is shared by almost all neuro-
degenerative disorders. This may partly reflect the level
of understanding and complexity of the biological pro-
cesses underpinning these disorders, and contrasts with
the promising interventions now in common use in
Table 5 Treatable ataxias
5.1 Gluten ataxia
Recommendation Grade
It is recommended that patients with idiopathic cerebellar ataxia are tested for gluten sensitivity. GPP
Consider testing for antibodies against TG6 (when possible) as a more sensitive test for gluten ataxia. C [32, 33]
Ataxia patients with or without enteropathy who have serological evidence of gluten sensitivity should be advised to start a gluten-free
diet without delay.
C [34]
Patients who are starting a gluten-free diet should be advised about strict adherence and given dietetic advice. GPP
Close monitoring is recommended with six-monthly testing to ensure for elimination of antigliadin antibodies. GPP
5.2 Ataxia with vitamin E deficiency
Recommendation Grade
Patients diagnosed with ataxia with vitamin E deficiency or abetalipoproteinemia should be treated with vitamin E supplements. C [35, 36]
5.3 Ataxia with vitamin B12 deficiency
Recommendation Grade
Patients diagnosed with ataxia and Vitamin B12 deficiency should be treated with Vitamin B12. GPP
5.4 Ataxia with CoQ10 (ubiquinone) deficiency
Recommendation Grade
Patients diagnosed with ataxia with CoQ10 deficiency should be treated with CoQ10 supplements. D [37–39]
Consider treatment of patients diagnosed with AOA1 with CoQ10 supplementation. D [40, 41]
5.5 Cerebrotendinous xanthomatosis
Recommendation Grade
Prompt diagnosis of cerebrotendinous xanthomatosis is advised in order to initiate treatment. GPP
If cerebrotendinous xanthomatosis is diagnosed treatment with chenodeoxycholic acid is recommended. B [42, 43]
5.6 Niemann-Pick type C (NPC)
Recommendation Grade
If NPC is suspected based on clinical investigations, perform diagnostic tests described above. Early diagnosis is important as it is a
treatable condition.
GPP
If NPC is diagnosed refer promptly to a Specialist Centre for treatment and management. GPP
Treatment with Miglustat is recommended in both adult and paediatric cases and is available in Specialist Centres. B [44–48]
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neuroinflammatory disorders such as Multiple Sclerosis.
In the more common ataxias, such as FRDA and some
SCAs, much research has focused on the identification
of therapeutic targets and indeed several treatment trials
have taken place. Furthermore, databases have been cre-
ated and natural history data are being collected by net-
works of researchers worldwide, and this effort is
proving useful in the design and implementation of trials
[13, 14]. Indeed, as a result of these developments, and
the financial incentives being provided for the study of
rare diseases generally, pharmaceutical and biotech com-
panies are increasingly engaging in ataxia research and
running trials often in collaboration with academic cen-
tres and patient groups, such as Ataxia UK. Given the
potential advantages of speedy development, drug repur-
posing approaches are also being explored by ataxia re-
searchers worldwide.
In addition to disease-modifying treatments, there are
specific symptoms experienced by patients with ataxia
(such as balance and coordination problems, tremor and
fatigue) for which effective therapies are also lacking yet
can cause significant disability. Ataxia UK has independ-
ently surveyed the opinions of 426 people with progres-
sive ataxia, to identify what they perceived to be their
most pressing medical needs. Interestingly, impairments
in balance, coordination and speech were highlighted as
the symptoms with greatest impact, as well as fatigue.
The production of these guidelines has revealed
considerable overlap between what are seen to be areas re-
quiring further research by professionals, and symptoms re-
quiring most amelioration identified by patients. More
research is thus needed to identify novel therapies and inter-
ventions to influence these symptoms, and critically to
evaluate their effectiveness.
In creating this comprehensive guidance, our aim has
been to provide a useful tool for HCPs looking after pa-
tients with progressive ataxia. Any comments on the
recommendations are welcomed by the Guidelines De-
velopment Group, in order to refine and improve these
recommendations in future editions.
Additional file
Additional file 1: Table S1. List of contributors. Table S2. Allied health
professional interventions. Table S3. Palliative care. (DOCX 27 kb)
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Recommendation Grade









Consider treating Hartnup disease with nicotinamide or tryptophan-rich diet, and advise patients on a high protein diet, sunlight protec-




Treat patients diagnosed with biotinidase deficiency with biotin. GPP
6.5 Pyruvate deficiency
Recommendation Grade
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